248 related articles for article (PubMed ID: 36915157)
1. Neutral effects of SGLT2 inhibitors in acute coronary syndromes, peripheral arterial occlusive disease, or ischemic stroke: a meta-analysis of randomized controlled trials.
Tsai PC; Chuang WJ; Ko AM; Chen JS; Chiu CH; Chen CH; Yeh YH
Cardiovasc Diabetol; 2023 Mar; 22(1):57. PubMed ID: 36915157
[TBL] [Abstract][Full Text] [Related]
2. The Effects of SGLT2 Inhibitors on Cardiovascular and Renal Outcomes in Diabetic Patients: A Systematic Review and Meta-Analysis.
Lo KB; Gul F; Ram P; Kluger AY; Tecson KM; McCullough PA; Rangaswami J
Cardiorenal Med; 2020; 10(1):1-10. PubMed ID: 31743918
[TBL] [Abstract][Full Text] [Related]
3. [Effects of SGLT2i on 24-hour ambulatory blood pressure in patients with type 2 diabetes complicating hypertension: a meta-analysis].
Tian L; Wang QY; Sun RM; Qi MM; Li YX; Gao X; Zhang LQ; Ma X; Shi H; Yu J; Bai F
Zhonghua Xin Xue Guan Bing Za Zhi; 2021 Oct; 49(10):1000-1011. PubMed ID: 34674438
[No Abstract] [Full Text] [Related]
4. Comparative efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for cardiovascular outcomes in type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials.
Täger T; Atar D; Agewall S; Katus HA; Grundtvig M; Cleland JGF; Clark AL; Fröhlich H; Frankenstein L
Heart Fail Rev; 2021 Nov; 26(6):1421-1435. PubMed ID: 32314085
[TBL] [Abstract][Full Text] [Related]
5. The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials.
Lin DS; Lee JK; Hung CS; Chen WJ
Diabetologia; 2021 Dec; 64(12):2676-2686. PubMed ID: 34536085
[TBL] [Abstract][Full Text] [Related]
6. Association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and lower extremity amputation: A systematic review and meta-analysis.
Heyward J; Mansour O; Olson L; Singh S; Alexander GC
PLoS One; 2020; 15(6):e0234065. PubMed ID: 32502190
[TBL] [Abstract][Full Text] [Related]
7. Impact of SGLT2 inhibitors on patient outcomes: a network meta-analysis.
Chen JY; Pan HC; Shiao CC; Chuang MH; See CY; Yeh TH; Yang Y; Chu WK; Wu VC
Cardiovasc Diabetol; 2023 Oct; 22(1):290. PubMed ID: 37891550
[TBL] [Abstract][Full Text] [Related]
8. Sodium-Glucose Cotransporter-2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta-Analysis of Randomized Trials and Systematic Review.
Rahman H; Khan SU; Lone AN; Ghosh P; Kunduru M; Sharma S; Sattur S; Kaluski E
J Am Heart Assoc; 2023 Aug; 12(16):e030578. PubMed ID: 37581396
[TBL] [Abstract][Full Text] [Related]
9. Association between sodium-glucose cotransporter-2 inhibitors and risk of sudden cardiac death or ventricular arrhythmias: a meta-analysis of randomized controlled trials.
Sfairopoulos D; Zhang N; Wang Y; Chen Z; Letsas KP; Tse G; Li G; Lip GYH; Liu T; Korantzopoulos P
Europace; 2022 Jan; 24(1):20-30. PubMed ID: 34333592
[TBL] [Abstract][Full Text] [Related]
10. Sodium-Glucose Cotransporter 2 Inhibitors, All-Cause Mortality, and Cardiovascular Outcomes in Adults with Type 2 Diabetes: A Bayesian Meta-Analysis and Meta-Regression.
Odutayo A; da Costa BR; Pereira TV; Garg V; Iskander S; Roble F; Lalji R; Hincapié CA; Akingbade A; Rodrigues M; Agarwal A; Lawendy B; Saadat P; Udell JA; Cosentino F; Grant PJ; Verma S; Jüni P
J Am Heart Assoc; 2021 Sep; 10(18):e019918. PubMed ID: 34514812
[TBL] [Abstract][Full Text] [Related]
11. Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors and Combined SGLT1/2 Inhibitors on Cardiovascular, Metabolic, Renal, and Safety Outcomes in Patients with Diabetes: A Network Meta-Analysis of 111 Randomized Controlled Trials.
Teo YN; Ting AZH; Teo YH; Chong EY; Tan JTA; Syn NL; Chia AZQ; Ong HT; Cheong AJY; Li TY; Poh KK; Yeo TC; Chan MY; Wong RCC; Chai P; Sia CH
Am J Cardiovasc Drugs; 2022 May; 22(3):299-323. PubMed ID: 35316484
[TBL] [Abstract][Full Text] [Related]
12. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis.
Li HL; Lip GYH; Feng Q; Fei Y; Tse YK; Wu MZ; Ren QW; Tse HF; Cheung BY; Yiu KH
Cardiovasc Diabetol; 2021 May; 20(1):100. PubMed ID: 33962654
[TBL] [Abstract][Full Text] [Related]
13. Comparison of cardiovascular and renal outcomes between dapagliflozin and empagliflozin in patients with type 2 diabetes without prior cardiovascular or renal disease.
Lim J; Hwang IC; Choi HM; Yoon YE; Cho GY
PLoS One; 2022; 17(10):e0269414. PubMed ID: 36251654
[TBL] [Abstract][Full Text] [Related]
14. Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease.
Zhang Y; Jiang L; Wang J; Wang T; Chien C; Huang W; Fu X; Xiao Y; Fu Q; Wang S; Zhao J
Cardiovasc Diabetol; 2022 Nov; 21(1):232. PubMed ID: 36335326
[TBL] [Abstract][Full Text] [Related]
15. Protective Effects of Sodium-Glucose Transporter 2 Inhibitors on Atrial Fibrillation and Atrial Flutter: A Systematic Review and Meta- Analysis of Randomized Placebo-Controlled Trials.
Li D; Liu Y; Hidru TH; Yang X; Wang Y; Chen C; Li KHC; Tang Y; Wei Y; Tse G; Xia Y
Front Endocrinol (Lausanne); 2021; 12():619586. PubMed ID: 33815278
[TBL] [Abstract][Full Text] [Related]
16. Comparison the effects of finerenone and SGLT2i on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus: A network meta-analysis.
Li X; Wu H; Peng H; Jiang H
Front Endocrinol (Lausanne); 2022; 13():1078686. PubMed ID: 36589800
[TBL] [Abstract][Full Text] [Related]
17. Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta-regression.
Musso G; Sircana A; Saba F; Cassader M; Gambino R
PLoS Med; 2020 Dec; 17(12):e1003461. PubMed ID: 33373368
[TBL] [Abstract][Full Text] [Related]
18. SGLT2 inhibitors and lower limb complications: an updated meta-analysis.
Lin C; Zhu X; Cai X; Yang W; Lv F; Nie L; Ji L
Cardiovasc Diabetol; 2021 Apr; 20(1):91. PubMed ID: 33910574
[TBL] [Abstract][Full Text] [Related]
19. Comparative Cardiovascular Outcomes of SGLT2 Inhibitors in Type 2 Diabetes Mellitus: A Network Meta-Analysis of Randomized Controlled Trials.
Jiang Y; Yang P; Fu L; Sun L; Shen W; Wu Q
Front Endocrinol (Lausanne); 2022; 13():802992. PubMed ID: 35370961
[TBL] [Abstract][Full Text] [Related]
20. Effects of SGLT2 inhibitors on cardiovascular, renal, and major safety outcomes in heart failure: A meta-analysis of randomized controlled trials.
Li X; Zhang Q; Zhu L; Wang G; Ge P; Hu A; Sun X
Int J Cardiol; 2021 Jun; 332():119-126. PubMed ID: 33838152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
